Navigation Links
The Ensign Group, Inc. Reports Third Quarter 2007 Earnings
Date:12/21/2007

ebuilding quarter for us, and we are excited about the prospect for organic revenue and earnings growth as we continue to intensify our focus on improved clinical performance, increased occupancy and enhanced patient mix in 2008."

Mr. Christensen added, "The recent completion of our initial public offering adds strength to our already-strong balance sheet, and we believe that, among other things, it enhances our ability to continue executing on our disciplined growth strategy."

Recent Highlights

IPO: On November 8, 2007, Ensign completed its Initial Public Offering (IPO), with net proceeds to the Company of $56.5 million after underwriting fees and offering expenses. The Company sold 4.0 million shares of common stock at $16.00 each. In addition, the entire 600,000 share over-allotment option described in the Company's prospectus was also exercised by the underwriters in November. Concurrent with the close of the IPO, all previously outstanding shares of the Company's preferred stock converted into an aggregate of 2,741,000 shares of common stock.

Recent Acquisitions: On December 11, 2007, Company subsidiaries completed their purchase of two skilled nursing facilities in California and one assisted living facility in Arizona for an aggregate purchase price of approximately $12.8 million. The three facilities include 123 skilled nursing beds, 90 assisted living units and 84 independent living units. The acquisitions were completed by three separate holding affiliates of The Ensign Group, Inc. Prior to the acquisitions, three operating subsidiaries of The Ensign Group, Inc. operated these three facilities under a master lease agreement with the seller, which was terminated upon the closing of the transaction. These three operators will continue to operate their respective facilities under new leases with the acquiring Ensign affiliates.

Proceeds of Ensign's recent IPO were used to fund the transactions. These acquisitions bring the n
'/>"/>

SOURCE The Ensign Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. The Ensign Group, Inc. to Announce Third Quarter 2007 Financial Results
2. The Ensign Group, Inc. Acquires Assets of Three Previously Leased Facilities
3. Karen Vigil Named Senior Vice President and Chief Executive Officer, Blue Shield of Californias Individual, Small Group, and Government Business Unit
4. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
5. Air Methods Completes Acquisition of FSS Airholdings, Inc., Parent Company of CJ Systems Aviation Group, Inc.
6. Nyer Medical Group, Inc. Reports EPS of $.02 on Record Revenues of $69.9 Million for Fiscal Year Ended 2007
7. The Mattson Jack Group, Inc. Announces the Release of the New Comorbidity Database(TM)
8. Congress Declares Long Term Care Awareness Week - Long Term Care Group, Inc. Continues Related Work
9. Hanger Orthopedic Group, Inc. Announces Record Revenue of $162.3 Million and 20% Growth in Earnings Per Share for the Quarter Ended September 30, 2007
10. Major EU Funded Nanotube Research Group, DESYGN-IT, Publish in AZoJono - The Open Access Online Nanotech Journal
11. itLinkz Group, Inc. Changes Name to China YCT International Group, Inc. and Effects Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... December 15, 2014 Cancer researchers have ... underlying genetic causes of deadly malignant pleural mesothelioma. Surviving ... on their website. Click here to read it ... of Hawaii Cancer Center, and New York’s Langone Medical ... pleural mesothelioma patients in an effort to pinpoint ...
(Date:12/15/2014)... Palm Beach, FL (PRWEB) December 15, 2014 ... Care , knows that holidays can be a daze of ... From slips and falls while decking halls, to burns when ... plenty of holiday hazards that can happen at any time. ... for pain, MD Now has made a list of helpful ...
(Date:12/15/2014)... MA (PRWEB) December 15, 2014 ... management solutions, announced today that it has received ... Quality Assurance (NCQA) for its Disease Management (DM) ... pulmonary disease (COPD), coronary heart disease and diabetes. ... from NCQA for Health Dialog’s Disease Management (DM) ...
(Date:12/15/2014)... December 15, 2014 The increase in prevalence ... of the main factors which is contributing to the growth ... the diagnosis and treatment of hearing loss and balance disorders ... three parts - microphone, speaker and amplifier. The global market ... of 6.01% during the period from 2014 to 2019. Some ...
(Date:12/15/2014)... 2014 In support of high-quality ... to restrictive state laws that may have unintended ... important area of public health policy. , The ... Integrity of Independent Review, contends that state legislation ... peer review determinations can result in subpar outcomes ...
Breaking Medicine News(10 mins):Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4Health News:NAIRO Calls for Higher Quality Independent Peer Review By Ending Restrictive State Laws 2
... Reporter , MONDAY, Sept. 27 (HealthDay News) -- Implantable ... of thousands of Americans at risk for sudden cardiac ... these medical devices have gotten a bad reputation in ... that connect the ICD to the heart can sometimes ...
... Australia and Hong Kong have conducted a comprehensive study ... of female attractiveness. The study, published in the ... divides young, tall and long armed women were considered ... important determining factor for evolutionary, social and economic success," ...
... their international colleagues have discovered genetic variants that lead ... taking aromatase inhibitors to treat their breast cancer. This ... halt their lifesaving medication. The findings appear today in ... . "Many women stop taking aromatase inhibitors due ...
... HealthDay Reporter , MONDAY, Sept. 27 (HealthDay News) -- ... risk of dying in the hospital and help their doctors ... Hospitals also can use the prediction tool to ... Eric Smith, assistant professor of neurology at the University of ...
... Onconova Therapeutics, Inc. is presenting new data in ... several studies with the company,s radioprotectant Ex-RAD at the ... September 25-29 in Maui, Hawaii. In vivo studies ... increase in survival versus placebo-treated groups in mice exposed ...
... place Jan. 13-16, 2011 at the Wynn Las Vegas. ... (each morning), observing differences in technique from a variety ... Lectures and plenary sessions will cover topics as bladder, ... to treat patients with benign prostate cancer. , Also ...
Cached Medicine News:Health News:New Software for Defibrillators Lowers Risk of Unnecessary Shocks 2Health News:New Software for Defibrillators Lowers Risk of Unnecessary Shocks 3Health News:Unlocking the secret of beauty: Scientists discover the complexities of attractive female bodies 2Health News:Mayo collaboration finds source of breast drug side effect 2Health News:New Tool Helps Predict Stroke Patient's Risk of Death in Hospital: Study 2Health News:New Tool Helps Predict Stroke Patient's Risk of Death in Hospital: Study 3Health News:Onconova Therapeutics presents new data demonstrating radioprotection by Ex-RAD at RRS annual meeting 2Health News:Onconova Therapeutics presents new data demonstrating radioprotection by Ex-RAD at RRS annual meeting 3
(Date:12/17/2014)... 2014 With advancements in neurological and ... is seeing new growth, according to Kalorama Information. ... for the majority of market volume, newer 3T ... which are creating opportunities for more sophisticated applications. The ... at a rate of 4%, with world market ...
(Date:12/17/2014)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII ... and commercializing innovative therapies addressing major unmet medical ... in its first Phase 2a study, RXI-109-1301.  The ... 1-month findings that were reported in September of ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , , ...
(Date:12/15/2014)... and Markets ( http://www.researchandmarkets.com/research/bf3b6l/electrocardiogram ) has announced ... Global Trends, Estimates and Forecasts, 2012-2018" report to ... Global Electrocardiogram Devices (ECG) sector is projected ... North America accounts for nearly 36% (2015) ... claims approximately 27% (2018). Asia-Pacific ...
Breaking Medicine Technology:Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4
... no additional very late stent thrombosis, NATICK, ... Corporation (NYSE: BSX ) today announced five-year ... demonstrating continued,long-term safety and efficacy for the TAXUS(R) ... showed no additional stent,thrombosis between years four and ...
... Aug. 30 ViroPharma Incorporated,(Nasdaq: VPHM ) today ... financial officer of ViroPharma, will present,at the Thomas Weisel ... September 5, 2007. The conference is being held at ... will also present at the 14th Annual BioCentury Newsmakers,in ...
Cached Medicine Technology:Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent 2Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent 3Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent 4ViroPharma to Present at Three Upcoming Healthcare Conferences 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: